Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
6.88
-4.22 (-38.02%)
At close: May 20, 2025, 4:00 PM
6.23
-0.65 (-9.45%)
After-hours: May 20, 2025, 7:59 PM EDT

Protagenic Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
2.051.761.211.9731.85
Upgrade
Research & Development
3.363.943.321.591.140.7
Upgrade
Operating Expenses
5.415.74.533.564.142.55
Upgrade
Operating Income
-5.41-5.7-4.53-3.56-4.14-2.55
Upgrade
Interest Expense
---0.11-0.14-0.5-0.25
Upgrade
Interest & Investment Income
0.040.040.260.190.030
Upgrade
Other Non Operating Income (Expenses)
----0.080.25
Upgrade
EBT Excluding Unusual Items
-5.37-5.66-4.37-3.51-4.52-2.55
Upgrade
Gain (Loss) on Sale of Investments
0.050.05-0.63-0.05-0-
Upgrade
Other Unusual Items
0.080.08----
Upgrade
Pretax Income
-5.24-5.53-5-3.56-4.52-2.55
Upgrade
Net Income
-5.24-5.53-5-3.56-4.52-2.55
Upgrade
Net Income to Common
-5.24-5.53-5-3.56-4.52-2.55
Upgrade
Shares Outstanding (Basic)
000000
Upgrade
Shares Outstanding (Diluted)
000000
Upgrade
Shares Change (YoY)
28.54%12.78%0.62%17.17%42.57%0.76%
Upgrade
EPS (Basic)
-13.05-15.79-16.11-11.53-17.18-13.80
Upgrade
EPS (Diluted)
-13.05-15.79-16.11-11.53-17.18-13.80
Upgrade
Free Cash Flow
-3.63-4.22-3.85-2-2.8-1.35
Upgrade
Free Cash Flow Per Share
-9.03-12.05-12.42-6.47-10.63-7.30
Upgrade
EBITDA
-5.36-5.65-4.5-3.56-4.14-2.55
Upgrade
D&A For EBITDA
0.050.050.03000
Upgrade
EBIT
-5.41-5.7-4.53-3.56-4.14-2.55
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q